UB Paderborn / Katalog / Suche / in CDI

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

The Lancet (British edition), 2016-12, Vol.388 (10062), p.2873-2884

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2015-12, Vol.40 (13), p.3053-3060

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke

Stroke (1970), 2014-11, Vol.45 (11), p.3304-3310

2014

Link zum Volltext

Verfügbarkeit prüfen

Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia

Neurotherapeutics, 2023-03, Vol.20 (2), p.431-451

2023

Link zum Volltext

Verfügbarkeit prüfen

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS

Frontiers in neuroscience, 2024-02, Vol.18, p.1348157

2024

Link zum Volltext

Verfügbarkeit prüfen

The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators

Journal of Alzheimer's disease, 2023-01, Vol.92 (1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an alpha 7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2015-12, Vol.40 (13), p.3053-3060

2015

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic criteria for apathy in neurocognitive disorders

Alzheimer's & dementia, 2021-12, Vol.17 (12), p.1892-1904

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

Journal of Alzheimer's disease, 2022, Vol.86 (3), p.1399

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus

BMC ear, nose and throat disorders, 2011-01, Vol.11 (1), p.1-1, Article 1

2011

Link zum Volltext

Verfügbarkeit prüfen

Clusterization of Behavioral and Psychological Symptoms of Dementia as Assessed by Neuropsychiatric Inventory: A Case Against the Use of Principal Component Analysis

Journal of Alzheimer's disease, 2024-01, Vol.98 (4), p.1483

2024

Link zum Volltext

Verfügbarkeit prüfen

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease

Alzheimer's & dementia, 2021-12, Vol.17 (S5), p.n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S15), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

Alzheimer's & dementia, 2023-12, Vol.19 (S18)

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an [alpha]7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2015-12, Vol.40 (13), p.3053

2015

Link zum Volltext

Verfügbarkeit prüfen

The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhD

Neurology live (Print), 2023-07

Moebius, Hans J

2023

Link zum Volltext

Verfügbarkeit prüfen

Neuroprotection and Inflammation Reduction, Improvement in Biomarkers From ACT-AD Study: Hans J. Moebius, MD, PhD

Neurology live (Print), 2023-05

Moebius, Hans J

2023

Link zum Volltext

Verfügbarkeit prüfen

Purification, Molecular Cloning, and Expression of the Mammalian sigma1-Binding Site

Proceedings of the National Academy of Sciences - PNAS, 1996-07, Vol.93 (15), p.8072-8077

1996

Link zum Volltext

Verfügbarkeit prüfen

Memantine in Moderate-to-Severe Alzheimer's Disease

The New England journal of medicine, 2003-04, Vol.348 (14), p.1333-1341

2003

Link zum Volltext

Verfügbarkeit prüfen

Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation

The Journal of biological chemistry, 2003-03, Vol.278 (13), p.10963-10972

2003

Link zum Volltext

Verfügbarkeit prüfen

Literarische Formen des Erinnerns: Die Deutschsprachige Gegenwartsliteratur Zwischen Aufstörung und Stabilisierung

1, 2024

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke

Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS

The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an alpha 7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Diagnostic criteria for apathy in neurocognitive disorders

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus

Clusterization of Behavioral and Psychological Symptoms of Dementia as Assessed by Neuropsychiatric Inventory: A Case Against the Use of Principal Component Analysis

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease

Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease

ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an [alpha]7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhD

Neuroprotection and Inflammation Reduction, Improvement in Biomarkers From ACT-AD Study: Hans J. Moebius, MD, PhD

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock

Purification, Molecular Cloning, and Expression of the Mammalian sigma1-Binding Site

Memantine in Moderate-to-Severe Alzheimer's Disease

Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation

Literarische Formen des Erinnerns: Die Deutschsprachige Gegenwartsliteratur Zwischen Aufstörung und Stabilisierung

Suchergebnisse filtern